Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prognostic utility of human complement factor H related protein test (the BTA stat ®Test)

British Journal of Cancer volume 85, pages 552–556 (2001)Cite this article

This article has been updated

Abstract

The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com

Download PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Corey MJ, Kinders RJ, Brown L, Rowley H and Vessela R (1998) Factor H related proteins are upregulated in bladder cancer. Proc Am Assn Cancer Res 39: 263 (abstr)

    Google Scholar 

  • Fitzpatrick JM, West AB and Butler MR (1986) Superficial bladder tumours (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection. J Urol 135: 920–922

    CAS  Article  Google Scholar 

  • Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin BB, Perrone TL and Szyfelbein WA (1982) Ta and T1 bladder cancer: Location, recurrence and progression. Br J Urol 54: 152–157

    CAS  Article  Google Scholar 

  • Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann M and Hawkins IR (1983) Superficial bladder cancer: progression and recurrence. J Urol 130: 1083–1086

    CAS  Article  Google Scholar 

  • Kiemeney LALM, Witjes JA, Heijbroek RP, Verbeek ALM and Debruyne FMJ (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150: 60–64

    CAS  Article  Google Scholar 

  • Kinders R, Root R, Jones J, Bruce C and Hass M (1997a) Complement factor H-related proteins are expressed in bladder cancer. Proceedings of the Eighty–Eighth Annual Meeting of American Association for Cancer Research, San Diego, CA USA 38: 29, Abstract No. 189

    Google Scholar 

  • Kinders R, Jones J, Root R, Murchison H, Bruce C, Williams L and Hass M (1997b) Human bladder Tumour antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 157: 28, Abstract no. 110

    Google Scholar 

  • Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, Williams L, Enfield D and Hass GM (1998) Complement Factor H or a related protein is a marker for transitional cell cancer of the bladder. Clinical Cancer Research 4: 2511–2520

    CAS  PubMed  Google Scholar 

  • Koch M, Hill GB and McPhee S (1986) Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 76: 1025–1029

    CAS  PubMed  Google Scholar 

  • Kurth KH, Denis L, Bouffioux CH, Sylvester R, Debruyne FM, Pavone–Macaluso M and Oosterlink W (1995) Factors effecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A: 1840–1846

    CAS  Article  Google Scholar 

  • Lutzeyer W, Rübben H and Dahm H (1982) Prognostic parameters in superficial bladder cancer: and analysis of 315 cases. J Urol 127: 250–252

    CAS  Article  Google Scholar 

  • Malmström P–U, Busch C and Norlén BJ (1987) Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 21: 185–195

    Article  Google Scholar 

  • Morris SB, Gordon EM, Shearer RJ and Woodhouse CRJ (1995) Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?. Br J Urol 75: 193–196

    CAS  Article  Google Scholar 

  • Mostofi FK, Sobin LH and Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization: Geneva

  • Parmar MKB, Freedman LS, Hargreave TB and Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer. J Urol 142: 284–288

    CAS  Article  Google Scholar 

  • Parmar MKB and Machin D (1995) Survival analysis. A practical approach John Wiley Chichester

    Google Scholar 

  • Pode D, Shapiro A, Wald M, Nativ O, Laufer M and Kaver I (1999) Noninvasive detection of bladder cancer with the BTA stat test. J Urol 161: 443–446

    CAS  Article  Google Scholar 

  • Raitanen M-P and Tammela TLJ (1995) Impact of tumour grade, stage, number and size, smoking and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir et Gyn 84: 37–41

    CAS  Google Scholar 

  • Raitanen M-P, Marttila T, Kaasinen E, Rintala E, Aine R and Tammela TLJ (2000) Sensitivity of human complement factor H related protein (the BTA stat Test) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 163: 1689–1692

    CAS  Article  Google Scholar 

  • Sarosdy M, Hudson M, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schelhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA and Brunelle SL (1997) Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50: 349–353

    CAS  Article  Google Scholar 

  • SPSS (1999) Advanced Models 9.0. SPSS Inc: Chigaco

  • Thompson RA Jr, Campbell EW Jr and Kramer HC (1993) Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 149: 1010–1011

    Article  Google Scholar 

  • Union Internationale Contre le Cancer (1978) TNM Classification of Malignant Tumours. International Union Against Cancer: Geneva

Download references

Author information

Author notes

  1. The Finn Bladder Group: Members: M. Ala-Opas and K Tuhkanen, Kuopio University Hospital; T Forssel, Kymenlaakso Central Hospital, Kotka; P. Granbacka and C. Palmberg, Pietarsaari Hospital; T. Liukkonen, Mikkeli Central Hospital; H. Juusela, Hospital of Jorvi, Espoo; H. Korhonen, Satakunta Central Hospital, Pori; P. Hellström and O. Lukkarinen, Oulu University Hospital; M. Nurmi and P. Rajala, Turku University Hospital; J. Permi and V-M. Puolakka, Lappeenranta Central Hospital; E. Rintala, I. Perttilä, Helsinki University Hospital; T. Tammela and M-P. Raitanen, Tampere University Hospital; M. Leppilahti, M. Leskinen. M-P. Raitanen and T. Marttila, Seinäjoki Central Hospital, E. Kaasinen, Hyvinkää Hospital; J. Ervasti, Ähtäri Hospital; A. Mehik, Oulainen Hospital; R. Kauppinen and M. Rauvala, Rovaniemi Central Hospital; J. Viitanen, Pohjois-Karjala Central Hospital, Joensuu; E. Hansson and P. Nylund, Vaasa Central Hospital.

Affiliations

  1. Department of Urology, Tampere University Hospital, Box 2000, Tampere, 33521, Finland

    M-P Raitanen & T L J Tammela

  2. Department of Pathology, Tampere University Hospital, Box 2000, Tampere, 33521, Finland

    R Aine

  3. Department of Surgery, Hyvinkää Hospital, Hyvinkää, 05850, Finland

    E Kaasinen

  4. Department of Urology, Helsinki University Hospital, Hus, 00029, Finland

    E Rintala

  5. Department of Surgery, Vaasa Central Hospital, Vaasa, 65130, Finland

    E Hansson

  6. Medical Informatics Group and Department of Psychiatry, University of Oulu Medical School, Oulu, 90220, Finland

    P Nieminen

  7. Department of Surgery, Seinäjoki Central Hospital and the Finn Bladder Group, Seinäjoki, 60220, Finland

    M-P Raitanen

Authors
  1. M-P Raitanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Kaasinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Rintala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Hansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Nieminen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Aine
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T L J Tammela
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Finn Bladder Group

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Raitanen, MP., Kaasinen, E., Rintala, E. et al. Prognostic utility of human complement factor H related protein test (the BTA stat ®Test). Br J Cancer 85, 552–556 (2001). https://doi.org/10.1054/bjoc.2001.1938

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1054/bjoc.2001.1938

Keywords

  • bladder neoplasms
  • tumour marker
  • prognosis

Further reading

Search

Advanced search

Quick links